247 related articles for article (PubMed ID: 22366992)
1. Progestin therapy for endometrial cancer: the potential of fourth-generation progestin (review).
Banno K; Kisu I; Yanokura M; Tsuji K; Masuda K; Ueki A; Kobayashi Y; Yamagami W; Nomura H; Susumu N; Aoki D
Int J Oncol; 2012 Jun; 40(6):1755-62. PubMed ID: 22366992
[TBL] [Abstract][Full Text] [Related]
2. Dienogest, a novel synthetic steroid, overcomes hormone-dependent cancer in a different manner than progestins.
Katsuki Y; Shibutani Y; Aoki D; Nozawa S
Cancer; 1997 Jan; 79(1):169-76. PubMed ID: 8988742
[TBL] [Abstract][Full Text] [Related]
3. Development of a mouse model for testing therapeutic agents: the anticancer effect of dienogest on endometrial neoplasms.
Saito F; Tashiro H; Yamaguchi M; Honda R; Ohba T; Suzuki A; Katabuchi H
Gynecol Endocrinol; 2016; 32(5):403-7. PubMed ID: 26680656
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Zhao S; Chen X; Lu X; Yu Y; Feng Y
Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
[TBL] [Abstract][Full Text] [Related]
5. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.
Ramirez PT; Frumovitz M; Bodurka DC; Sun CC; Levenback C
Gynecol Oncol; 2004 Oct; 95(1):133-8. PubMed ID: 15385122
[TBL] [Abstract][Full Text] [Related]
6. Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Zhang H; Yan L; Bai Y; Li C; Guo Q; Wang C; Zhao X; Li M
Gynecol Oncol; 2015 Mar; 136(3):549-53. PubMed ID: 25451692
[TBL] [Abstract][Full Text] [Related]
7. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer.
Lai CH; Huang HJ
Curr Opin Obstet Gynecol; 2006 Feb; 18(1):29-34. PubMed ID: 16493257
[TBL] [Abstract][Full Text] [Related]
8. Molecular tools to reestablish progestin control of endometrial cancer cell proliferation.
Dai D; Kumar NS; Wolf DM; Leslie KK
Am J Obstet Gynecol; 2001 Apr; 184(5):790-7. PubMed ID: 11303185
[TBL] [Abstract][Full Text] [Related]
9. [Outcome analysis of conservative treatment of well-differentiated endometrial adenocarcinoma and severe atypical hyperplasia in young women].
Yu M; Shen K; Yang JX; Huang HF; Wu M; Pan LY; Lang JH; Lian LJ
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):242-5. PubMed ID: 16759458
[TBL] [Abstract][Full Text] [Related]
10. Dienogest in the treatment of endometriosis.
Bizzarri N; Remorgida V; Leone Roberti Maggiore U; Scala C; Tafi E; Ghirardi V; Salvatore S; Candiani M; Venturini PL; Ferrero S
Expert Opin Pharmacother; 2014 Sep; 15(13):1889-902. PubMed ID: 25069386
[TBL] [Abstract][Full Text] [Related]
11. [Hormone therapy of endometrial carcinoma].
Kuramoto H; Jobo T; Kato Y; Tateoka K; Sato R
Gan To Kagaku Ryoho; 1996 May; 23(6):673-7. PubMed ID: 8645016
[TBL] [Abstract][Full Text] [Related]
12. Increased natural killer cells and decreased regulatory T cells are seen in complex atypical endometrial hyperplasia and well-differentiated carcinoma treated with progestins.
Witkiewicz AK; McConnell T; Potoczek M; Emmons RV; Kurman RJ
Hum Pathol; 2010 Jan; 41(1):26-32. PubMed ID: 19733383
[TBL] [Abstract][Full Text] [Related]
13. Hormonal treatment of endometrial cancer: past, present and future.
Podczaski E; Mortel R
Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):469-89. PubMed ID: 11476566
[TBL] [Abstract][Full Text] [Related]
14. Conservative treatment of early endometrial cancer.
Bovicelli A; D'Andrilli G; Giordano A; De Iaco P
J Cell Physiol; 2013 Jun; 228(6):1154-8. PubMed ID: 23172641
[TBL] [Abstract][Full Text] [Related]
15. Reevaluating the safety of fertility-sparing hormonal therapy for early endometrial cancer.
Yang YC; Wu CC; Chen CP; Chang CL; Wang KL
Gynecol Oncol; 2005 Nov; 99(2):287-93. PubMed ID: 16051341
[TBL] [Abstract][Full Text] [Related]
16. [Endometrial adenocarcinoma in women 40 years old or younger by treatment with progestins: report of 6 cases and review of the literatures].
Wang HY; Shen L; Sun Z
Zhonghua Fu Chan Ke Za Zhi; 2006 Apr; 41(4):237-41. PubMed ID: 16759457
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Wang Y; Wang Y; Zhang Z; Park JY; Guo D; Liao H; Yi X; Zheng Y; Zhang D; Chambers SK; Zheng W
Oncotarget; 2016 Mar; 7(9):10363-72. PubMed ID: 26824415
[TBL] [Abstract][Full Text] [Related]
18. [Hormonal therapy for endometrial adenocarcinoma].
Susumu N; Aoki D; Suzuki N; Nozawa S
Gan To Kagaku Ryoho; 2001 Jul; 28(7):934-45. PubMed ID: 11478142
[TBL] [Abstract][Full Text] [Related]
19. Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
Amezcua CA; Lu JJ; Felix JC; Stanczyk FZ; Zheng W
Gynecol Oncol; 2000 Nov; 79(2):169-76. PubMed ID: 11063639
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia--precursor of endometrial cancer.
Wang S; Pudney J; Song J; Mor G; Schwartz PE; Zheng W
Gynecol Oncol; 2003 Feb; 88(2):108-17. PubMed ID: 12586588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
